Dr. Mohammed Aamir Ali, MD Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 5550 Friendship Blvd Ste T90, Chevy Chase, MD 20815 Phone: 240-737-0085 Fax: 202-296-0301 |
Dr. Richard E. Rubin, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5530 Wisconsin Ave, Suite 750, Chevy Chase, MD 20815 Phone: 301-654-6442 Fax: 301-654-4237 |
Dr. William E. Battle, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5530 Wisconsin Ave Ste 700, Chevy Chase, MD 20815 Phone: 301-656-5050 Fax: 301-654-4237 |
Dr. Alan M. Weintraub, MD Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 5530 Wisconsin Ave, Suite 700, Chevy Chase, MD 20815 Phone: 301-654-6442 Fax: 301-654-1924 |
Dr. Michael T Keegan, M.D. Internal Medicine - Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 5550 Friendship Blvd, Suite T-90, Chevy Chase, MD 20815 Phone: 301-654-2521 Fax: 301-654-2986 |
News Archive
NEBioCalculator, a new online "conversions and calculations" tool developed by New England Biolabs, offers bench-side support for molecular biology experimental planning.
Isogenica Ltd today announced that it has executed a services agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Can treatment with high doses of a cholesterol-lowering statin drug improve outcomes for patients with stroke caused by rupture and bleeding of brain aneurysms? An ongoing clinical trial will soon find out, according to an article in the May issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.
In a recent medRxiv preprint research paper, scientists from India analyzed twenty European countries and showed that the prevalence of exposure to Mycobacterium spp. (which includes BCG vaccine) is consistently negatively correlated with coronavirus disease (COVID-19) infections.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group announced today the results of a clinical trial of its investigational Fluzone Quadrivalent (Influenza Virus Vaccine) compared to the currently licensed Fluzone (Influenza Virus Vaccine). Data from the Phase II trial assessing the immunogenicity and safety of the investigational quadrivalent vaccine were presented at the 48th Annual Meeting of the Infectious Diseases Society of America in Vancouver, British Columbia.
› Verified 9 days ago